Novo CEO is on the hunt for future growth: "The pressure is bigger than ever"
Lars Fruergaard Jørgensen and the rest of Novo Nordisk are starting to plan for the future, when the firm's crucial patents have expired. This is a big task that requires a lot of effort, the CEO says.
by BENJAMIN WERNER CHRISTENSEN, translated by catherine brett and daniel pedersen
The thought of executing another formidable decade with high growth and continued progress is a bit of a headache for the CEO of Novo Nordisk.
"The pressure is bigger than ever," says Lars Fruergaard Jørgensen to Danish media Finans.
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.